Analysis of the safety and efficacy of the currently marked oral anticoagulants was performed in patients after large joints arthroplasty. A total of 5025 patients after total knee arthroplasty and 5216 patients after...Analysis of the safety and efficacy of the currently marked oral anticoagulants was performed in patients after large joints arthroplasty. A total of 5025 patients after total knee arthroplasty and 5216 patients after total hip arthroplasty were examined. All patients were divided into groups by the prescribed anticoagulant. The duration of anticoagulant therapy was 35 days and 6 weeks after surgery, respectively. Ultrasonography of the lower extremities veins was performed in all patients prior to the surgery and 5 days after surgery. In patients receiving Dabigatran, the incidence of clinically significant deep vein thrombosis was lower compared with patients receiving Rivaroxaban and Apixaban; in contrast, the rate of postoperative hematomas in the last two groups was higher.展开更多
文摘Analysis of the safety and efficacy of the currently marked oral anticoagulants was performed in patients after large joints arthroplasty. A total of 5025 patients after total knee arthroplasty and 5216 patients after total hip arthroplasty were examined. All patients were divided into groups by the prescribed anticoagulant. The duration of anticoagulant therapy was 35 days and 6 weeks after surgery, respectively. Ultrasonography of the lower extremities veins was performed in all patients prior to the surgery and 5 days after surgery. In patients receiving Dabigatran, the incidence of clinically significant deep vein thrombosis was lower compared with patients receiving Rivaroxaban and Apixaban; in contrast, the rate of postoperative hematomas in the last two groups was higher.